Immune checkpoint therapy-current perspectives and future directions

Padmanee Sharma; Sangeeta Goswami; Deblina Raychaudhuri; Bilal A Siddiqui; Pratishtha Singh; Ashwat Nagarajan; Jielin Liu; Sumit K Subudhi; Candice Poon; Kristal L Gant; Shelley M Herbrich; Swetha Anandhan; Shajedul Islam; Moran Amit; Gayathri Anandappa; James P Allison

doi:10.1016/j.cell.2023.03.006

Immune checkpoint therapy-current perspectives and future directions

Cell. 2023 Apr 13;186(8):1652-1669. doi: 10.1016/j.cell.2023.03.006.

Authors

Padmanee Sharma¹, Sangeeta Goswami², Deblina Raychaudhuri³, Bilal A Siddiqui⁴, Pratishtha Singh³, Ashwat Nagarajan⁴, Jielin Liu⁵, Sumit K Subudhi⁴, Candice Poon⁶, Kristal L Gant⁴, Shelley M Herbrich⁴, Swetha Anandhan⁵, Shajedul Islam⁷, Moran Amit⁷, Gayathri Anandappa⁸, James P Allison⁹

Affiliations

¹ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: padsharma@mdanderson.org.
² Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; MD Anderson UT Health Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁷ Department of Head & Neck Surgery Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁸ Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁹ Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 37059068
DOI: 10.1016/j.cell.2023.03.006

Abstract

Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer patients and conferred durable clinical benefits, including cure in a subset of patients. Varying response rates across tumor types and the need for predictive biomarkers to optimize patient selection to maximize efficacy and minimize toxicities prompted efforts to unravel immune and non-immune factors regulating the responses to ICT. This review highlights the biology of anti-tumor immunity underlying response and resistance to ICT, discusses efforts to address the current challenges with ICT, and outlines strategies to guide the development of subsequent clinical trials and combinatorial efforts with ICT.

Keywords: CTLA-4; ICT; PD-1; PD-L1; combinatorial biomarkers; cytotoxic T lymphocyte-associated protein 4; immune checkpoint therapy; immune-related adverse events; irAEs; programmed cell death protein 1; programmed death ligand 1; reverse translation.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

B7-H1 Antigen
Clinical Trials as Topic
Humans
Immune Checkpoint Inhibitors / administration & dosage
Immunotherapy*
Neoplasms* / drug therapy

Substances

B7-H1 Antigen
Immune Checkpoint Inhibitors